跳至主要内容
临床试验/CTRI/2024/06/068495
CTRI/2024/06/068495尚未招募不适用

Treatment of Focal Seizures Patients with Brivaracetam through a Multicenter, Real-World Study: Case Cohort Analysis

Torrent Pharmaceuticals Ltd.1 个研究点 分布在 1 个国家目标入组 2,100 人开始时间: 2024年6月16日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
2,100
试验地点
1
主要终点
Change in Seizure Frequency

研究概览

简要总结

  • This study is planned to evaluate the safety and effectiveness of brivaracetam in Indian patients with focal epilepsy.
  • Study design**:**Post Approval Observational Studies (PAOS).
  • Duration of Observation**:** 12 weeks (At least)
  • Study drug and dose: Brivaracetam 25 mg, 50 mg, 100 mg, 200 mg tablets.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 95.00 Year(s)(—)
性别
All

入选标准

  • Male or female patients with partial onset seizures with or without secondary generalization in patients 18 years of age and older with epilepsy.
  • Known cases brivaracetam receiving therapy for more than equal to 2 weeks.

排除标准

  • Patients allergic to brivaracetam or any of the ingredients in medicine.

结局指标

主要结局

Change in Seizure Frequency

时间窗: 4 weeks and 12 weeks

次要结局

  • Responders Rate(4 weeks and 12 weeks)
  • Seizure Freedom(4 weeks and 12 weeks)
  • Clinicians Global Impression – Efficacy Index (CGI-EI)(4 weeks and 12 weeks)
  • Quality of life(4 weeks and 12 weeks)
  • Patient’s treatment acceptability(4 weeks and 12 weeks)
  • Demographic pattern(Baseline)
  • Prevalence of other co-morbid conditions along with Focal Epilepsy(Baseline)
  • Other Anti-epileptic drugs (AEDs) used along with BRV.(Baseline, 4 weeks and 12 weeks)
  • Safety assessments in terms of AEs(4 weeks and 12 weeks)

研究者

发起方
Torrent Pharmaceuticals Ltd.
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Nikunj R Godhani

Karunesh Neuro and Spine SUrgical Hospital

研究点 (1)

Loading locations...

相似试验